ENHANCED PRODUCTION OF HIV-1 PROTEASE IN E COLI

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 11449
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1989
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Tbc Research Laboratories
950 Boston Ave, Longmont, CO, 80501
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
HUMAN IMMUNODEFICIENCY VIRUS TYPE I (HIV-1) IS THE ETIOLOGICAGENT OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). THIS PROJECT'S LONG-TERM OBJECTIVE IS TO STUDY THE ACTION OF THE HIV-1 PROTEASE TO DEVELOP SPECIFIC PROTEASE INHIBITORS THAT MIGHT BE ABLE TO HALT THE VIRAL REPLICATION. THIS STUDY IS POSSIBLE ONLY WITH THE AVAILABILITY OF LARGE QUANTITIES OF BIOLOGICALLY ACTIVE HIV-1 PROTEASE. PHASE I EFFORTS WILL DEVELOP A RECOMBINANT DNA SYSTEM TO PRODUCE THE PROTEASE. THE APPROACH TO BE USED WILL INVOLVE THE ASSEMBLY OF A SYNTHETIC GENE CODING FOR THE HIV-1 PROTEASE. THE GENE WILL BE CLONED INTO A PLASMID AND EXPRESSED IN ESCHERICHIA COLI. THE PRODUCTION LEVEL OF THE GENE PRODUCT WILL BE OPTIMIZED SO THAT THE PROTEASE CAN BE ECONOMICALLY PRODUCED. HIGH-LEVEL EXPRESSION OF THE PROTEASE WILL ENABLE PHASE II RESEARCH TO FOCUS ON THE E. COLI FERMENTATION SCALE-UP, PURIFICATION, AND RENATURATION OF THE PROTEASE TO YIELD BIOLOGICALLY ACTIVE HIV-1 PROTEASE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government